FindTrial
Sign In

The use of intravesical lignocaine to reduce pain and increase dwell time of intravesical mitomycin chemotherapy

The use of intravesical lignocaine to reduce pain and increase dwell time of intravesical mitomycin chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN65454120
Enrollment
Unknown
Registered
2003-09-12
Start date
2003-03-10
Completion date
Unknown
Last updated
2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia for intravesical mitomycin chemotheapy Cancer Malignant neoplasm of bladder

Interventions

30 min before mitomycin is instilled into the patients bladder, 40 ml 0.5% lignocaine or 40 ml saline (placebo) will be instilled. The catheter will then be clamped. After 30 min, the lignocaine/place

Sponsors

Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with transitional cell carcinoma of the bladder, following their first endoscopic resection.

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

MeasureTime frame
Visual analogue pain scores. Dwell time.—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026